Dow Jones
38.085,80 -375,12 (-0,98%) Nasdaq
15.611,76 -100,99 (-0,64%) Nikkei 225
37.934,76 +306,28 (+0,81%) EUR/USD
1,0733 0,0000 (-0,00%) Bitcoin EUR
60.044,50 +146,71 (+0,24%) CMC Crypto 200
1.391,98 -4,56 (-0,33%)
Autolus Therapeutics plc (AUTL)
Dopo ore:
| Chiusura precedente | 4,2100 |
| Aperto | 4,5200 |
| Denaro | 4,0800 x 300 |
| Lettera | 4,1000 x 300 |
| Min-Max giorno | 3,9600 - 4,2900 |
| Intervallo di 52 settimane | 1,6900 - 7,4500 |
| Volume | |
| Media Volume | 1.595.283 |
| Capitalizzazione | 1,085B |
| Beta (5 anni mensile) | 1,93 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,2000 |
| Prossima data utili | 14 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 10,69 |
GlobeNewswireCorrection - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2023 financial results and operational highlights before open of US markets on Thursday, November 2, 2023. Management will host a conference call and webcast at 9:00 am ET/1:00 pm GMT to discuss the company’s financial results and provide a general business updat
- GlobeNewswire
Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2023 financial results and operational highlights before open of US markets on Thursday, November 2, 2023. Management will host a conference call and webcast at 9:00 am ET/1:00 pm GMT to discuss the company’s financial results and provide a general business updat
- GlobeNewswire
Autolus Therapeutics announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia published in the journal Blood
Data support utility of AUTO1/22 approach in preventing antigen evasion in pediatric B-ALLComplete responses observed in patients with CD19 negative disease No antigen negative relapse seen in responding patients LONDON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces a publication on the AUTO1/22 Phase 1 study (CARPALL) in Pediatric B-cell Acute Lymphobl
